A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

Inclusion Criteria:

• Healthy male and female participants aged 18 to 55 years

• All females must have a negative pregnancy test at the Screening Visit and onadmission to the Clinical Unit.

• Female(s) of childbearing potential if heterosexually active, must agree to use anapproved method of highly effective contraception.

• Male participants must use condoms for the duration of clinical trial.

• Additional contraception must be used for the sexual partners of male trialparticipants throughout the clinical trial.

• Have a body mass index (BMI) between ≥ 20.0 and ≤ 35 kg/m2 (at the time ofscreening) inclusive and weigh at least 50 kg.

Exclusion Criteria:

• History of any clinically important disease or disorder (liver transplant, liverdisease, positive for serum HBsAg (Hepatitis B surface antigen) OR anti-HBcAb (Hepatitis B core antibody), positive for anti-HCV (Hepatitis C virus), history ofcirrhosis and/or hepatic decompensation, cardiovascular disease, neuromuscular orneurogenic disease.

• History of Type 1 or Type 2 diabetes mellitus (DM).

• History of Hemoglobin A1c ≥ 6.5% (≥ 48 mmol/mol) at screening.

• History or presence of gastrointestinal, hepatic, or renal disease or any othercondition known to interfere with absorption, distribution, metabolism, or excretionof drugs.

• Any clinically important illness, medical/surgical procedure, or trauma.

• Any laboratory values with deviations or clinically important abnormalities inclinical chemistry, hematology, or urinalysis at the Screening Visit or on admissionto the Clinical Unit.

• Significant hepatic disease as judged by the investigator.

• Any positive result on screening for serum HBsAg, HBcAb or HIV (Humanimmunodeficiency virus).

• Any clinically important abnormalities in rhythm, conduction, or morphology of theresting 12 lead ECG, at screening

• Abnormal vital signs.

• Uncontrolled thyroid disease or history/family history of medullary thyroidcarcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).

• Current smokers or those who have smoked or used nicotine products.

• Known or suspected history of alcohol or drug abuse or excessive intake of alcoholas judged by the investigator. Excessive intake of alcohol defined as the regularconsumption of more than 24 g of alcohol per day for men or 12 g of alcohol per dayfor females.

• Positive screen for drugs of abuse, or alcohol or cotinine at screening or on eachadmission to the Clinical Unit.

• History of severe allergy/hypersensitivity or ongoing clinically importantallergy/hypersensitivity.

• Excessive intake of caffeine-containing drinks or food

• History of psychosis or bipolar disorder or major depressive disorder or suicideattempt or suicidal ideation.